Head and Neck Squamous Cell Carcinoma

Details 286 Trials 13 Therapies

A squamous cell carcinoma that arises from any of the following anatomic sites: lip and oral cavity, nasal cavity, paranasal sinuses, pharynx, larynx, and salivary glands.

parent conditions

Head and Neck Carcinoma

Squamous Cell Carcinoma

child conditions

Oral Cavity Squamous Cell Carcinoma

Laryngeal Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma of Unknown Primary

Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma

Salivary Gland Squamous Cell Carcinoma

Lacrimal Gland Squamous Cell Carcinoma

Middle Ear Squamous Cell Carcinoma

Pharyngeal Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma of the Head and Neck

synonyms

SCCHN

HNSCC

Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck

Head and neck squamous cell carcinoma, NOS

Squamous Cell Carcinoma of the Head and Neck

Head and neck squamous cell carcinoma (HNSCC)

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

179 sites for NCT04590963

Head and Neck Squamous Cell Carcinoma

cetuximab, +1 more drug

immunotherapy, +1 more type

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

256 sites for NCT03952585

CDKN2A Overexpression, +1 more biomarker

Oropharyngeal Squamous Cell Carcinoma

nivolumab, +1 more drug

immunotherapy, +1 more type

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

151 sites for NCT03765918

Head and Neck Squamous Cell Carcinoma

cisplatin, +2 more drugs

chemotherapy, +2 more types

A Study of Debio 1143 (Xevinapant) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

221 sites for NCT04459715

HPV Negative

Hypopharyngeal Squamous Cell Carcinoma, +2 more conditions

cisplatin, +2 more drugs

chemotherapy, +2 more types

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)

128 sites for NCT04199104

Hypopharyngeal Squamous Cell Carcinoma, +3 more conditions

lenvatinib, +1 more drug

immunotherapy, +1 more type

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

78 sites for NCT02693535

AKT1 Mutation, +128 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +19 more conditions

abemaciclib, +23 more drugs

immunotherapy, +1 more type

Show 286 Trials for Head and Neck Squamous Cell Carcinoma

pembrolizumab

PD-L1 Expression (CPS >= 1)

Head and Neck Squamous Cell Carcinoma